Cambridge Healthtech Institute’s 16th Annual

Antibodies for Cancer Therapy

Driving Breakthrough Therapies

May 11-12, 2026

 

Cambridge Healthtech Institute's 16th annual Antibodies for Cancer Therapy conference explores the evolving role of antibody engineering in driving breakthroughs against cancer, with a focus on T cell engagers, bispecifics, and novel scaffolds that are expanding therapeutic potential. Sessions will highlight combination approaches with TCEs, checkpoint inhibitors, ADCs, and cytokines, alongside dual-targeting strategies and conditional/masking approaches to improve specificity and enhance safety, positioning antibodies and antibody-based therapies at the forefront of next-generation oncology.

 

Coverage will include, but is not limited to:

 

COMBINATION APPROACHES WITH TCEs—IMPROVING EFFICACY AND WIDENING INDICATION SPACE

  • Combination with standard of care (chemotherapy, targeted therapies)
  • Combination with ADCs
  • Will the combination with checkpoint inhibitors help?
  • Will costimulatory agonists help (CD28, 4-1BB, CD2)?
  • Will cytokines help?
  • Will epitope spreading help?
  • Combination with cancer vaccines
  • Combination with other immune cells, like NK cells (NKG2D) or macrophages (CD47)

DUAL TARGETING STRATEGIES—COMPARISON OF BISPECIFICS VS. COMBINATION

  • Dual or triple targeting (example of GPRC5D/BCMA combo)
  • Dual-blockade: eg PDL1xVEGF
  • Checkpoint x checkpoint
  • Checkpoint x tumor antigen
  • Tumor antigen x tumor antigen
  • Non-immune Targets: e.g., GITR×another checkpoint or PD-L1/TGF-β
  • Combination with effector cell agonists for dual activation pathways

MASKING/CONDITIONAL ANTIBODIES/MOLECULAR SWITCHES—IMPROVING SPECIFICITY AND REDUCING TOXICITY

  • Increasing target space by conditional approaches, pMHC targeting
  • Protease-mediated activation by removing mask
  • ATP-activatable antibodies
  • Probody-Drug Conjugates

NOVEL FORMATS AND ALTERNATIVE APPROACHES

  • CAR-T cell delivered effector scFvs to combat heterogeneity such as in GBM and PCA
  • Designing novel scaffolds beyond IgG: DARPins, affibodies, and miniproteins

EMERGING FRONTIERS AND DELIVERY METHODS

  • Oral and alternative delivery formats for antibodies
  • mRNA-Encoded Antibodies

 

The deadline for priority consideration is October 17, 2025.

 

AAll proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 


For more details on the conference, please contact:

Mimi Langley

Executive Director, Conferences

Cambridge Healthtech Institute

Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

Companies A-K

Jason Gerardi

Sr. Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-5452

Email: jgerardi@healthtech.com

 

Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-1340

Email: ashleyparsons@healthtech.com


Submit a Speaker Proposal

View By:


Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW   Nona_Biosciences_NEW